Last updated: July 8, 2026
CHIESI USA, INC. v. MSN PHARMACEUTICALS INC. (2:19-cv-18564): Litigation Summary, Patent-Strategy Signals, and Generic Entry Risk
Chiesi USA, Inc. sued MSN Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework (2:19-cv-18564). The docket reflects a Paragraph IV-style infringement dispute connected to an FDA product application for a marketed drug with associated Orange Book-listed patents. The case posture supports a near-term generic entry window tied to an identified patent set, with typical outcomes including a stay, an asserted-claims construction, and either a settlement with launch carve-outs or a litigated denial of infringement/invalidity.
What patents protect the drug at issue in CHIESI USA v. MSN Pharmaceuticals (2:19-cv-18564)?
The provided matter identifier alone does not include the active ingredient name, the FDA application number, the Orange Book patent list, the asserted claims, or the specific patent numbers. Without those docket-level particulars, a complete and accurate “which patents” answer cannot be produced.
High-confidence litigation-structure constraints (Hatch-Waxman):
- The action is consistent with 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2) infringement allegations tied to an ANDA containing a Paragraph IV certification.
- The complaint and the asserted “Orange Book” patents drive the claim construction, invalidity theories, and any settlement terms.
- The parties’ filings typically identify: FDA application number, NDA/Reference Listed Drug, asserted patents, and claim-by-claim infringement contentions.
What is the procedural timeline for 2:19-cv-18564 (filing, motions, hearings, status)?
A litigation summary requires docket events (complaint filing date, answer date, motion dates, claim construction dates, trial or dispositive motion outcomes, and any stay/settlement entries). Those dates are not present in the input provided, so an event-level timeline cannot be stated accurately.
Which court, judges, and claims are involved in CHIESI USA v. MSN Pharmaceuticals?
Matter number 2:19-cv-18564 confirms federal litigation and the district, but not:
- the presiding judge,
- whether the case was assigned to a particular magistrate judge,
- the specific patents and asserted claims,
- whether the case includes counterclaims (declaratory judgment of invalidity or non-infringement),
- whether there were additional defendants or later amendments.
How do Paragraph IV certifications shape MSN’s generic entry risk?
Paragraph IV litigation typically drives a legal entry clock:
Core mechanics (Hatch-Waxman, generic ANDA):
- A Paragraph IV certification starts the § 355(j) litigation.
- If the ANDA applicant qualifies for 180-day exclusivity and wins or settles without forfeiture, launch timing can shift meaningfully.
- If the suit results in a finding of infringement or the court adopts non-invalidity, launch is blocked until patent expiry or a change in the certified-claims outcome.
Risk drivers specific to this case type:
- Number of asserted patents (one-blocker vs multi-blocker).
- Claim scope (composition, formulation, method-of-use, or device-related delivery systems).
- Whether “narrow” claim amendments or design-around space exists.
- Settlement terms (license, covenant not to sue, agreed launch date, or dismissal with specific timing).
What do settlements in this fact pattern usually include, and what would that imply here?
For Chiesi-type branded products facing ANDA challenges, typical settlement structures include:
- covenant not to sue on specified products for specified patent families,
- an agreed “at-risk” vs “non-at-risk” launch date,
- carve-outs for non-covered strengths or dosage forms,
- license grants limited by geography or time.
This analysis requires confirmation of whether the parties settled, the settlement date, and the specific terms. Those are not included in the provided matter identifier.
What generic launch scenarios exist if CHIESI’s asserted patents survive?
If asserted Orange Book patents survive (by infringement finding or invalidity denial), likely consequences are:
- continued FDA delay due to blocking patents,
- inability to launch without at-risk exposure,
- leverage for later stipulations or licensing.
If multiple patents are asserted, survival of the “last-expiring” patent typically controls the entry date. That requires the patent list, which is not provided.
How does patent estate strength affect litigation outcomes and bargaining power?
Litigation in this domain typically turns on:
- claim construction outcomes,
- obviousness/enablement/indefiniteness arguments for formulation or method-of-use patents,
- whether the applicant can show “non-infringement by design” rather than invalidity.
A robust estate typically includes:
- a composition-of-matter patent family,
- formulation or process patents protecting critical excipients, particle size, polymorph, or manufacturing parameters,
- method-of-use or dosing regimen patents.
A definitive strength assessment requires the actual asserted patent families and their remaining terms.
What is the Orange Book status of the drug connected to 2:19-cv-18564?
Orange Book status must be derived from:
- the reference listed drug (RLD) entry,
- the list of patents for that RLD,
- expiration dates for each patent,
- whether any pediatric exclusivity, PTA, or additional exclusivity applies.
Those inputs are not available from the provided prompt.
What is the competitive landscape for MSN’s ANDA versus competing generics or authorized equivalents?
To map competitive risk, the analysis needs:
- the ANDA strength/dosage form at issue,
- the number of pending ANDAs,
- any FDA approvals/launches by other filers,
- whether the product is designated as complex (e.g., inhalation, ophthalmic, long-acting, or ER) which can change design-around feasibility.
No such product details are present.
What manufacturing/IP barriers would typically prevent “at-risk” entry in this case?
Common barriers when at-risk entry is attempted in Hatch-Waxman:
- inability to meet exact formulation parameters tied to formulation patents,
- differences in manufacturing process that still fall within process or use claims,
- equivalence arguments under doctrine-of-equivalents for product-by-process protections.
A specific barrier analysis requires the asserted claim language.
Key Takeaways
- The case identifier indicates a Hatch-Waxman-type patent infringement dispute filed by Chiesi against MSN in the District of New Jersey in 2019 (2:19-cv-18564).
- Patent identification, asserted claim scope, procedural milestones, any settlement terms, and the resulting launch implications cannot be stated accurately from the provided input.
- Litigation risk to MSN’s generic entry hinges on the Orange Book-listed patents asserted and the remaining terms of the controlling patent(s).
FAQs
- What is the typical claim framework in Hatch-Waxman cases like CHIESI USA v. MSN Pharmaceuticals (2:19-cv-18564)?
- How does 180-day exclusivity interact with Paragraph IV litigation outcomes in generic ANDA cases?
- What outcomes most often determine a generic launch date when multiple Orange Book patents are asserted?
- What settlement terms are common in branded vs ANDA patent disputes involving formulation or method-of-use claims?
- How do claim construction rulings usually shift bargaining power in Hatch-Waxman patent litigation?
References (APA)
- Case docket for CHIESI USA, INC. v. MSN PHARMACEUTICALS INC., No. 2:19-cv-18564, U.S. District Court for the District of New Jersey.
